CLAIMS

1. Use of any one of the following components or combinations of components:

5 C,

A and B,

A and C or C',

B and C or C',

A, B and C or C',

10 wherein

A is an antidepressant,

B is vitamin B_{12} , and

C is a precursor or inducer of a neurotransmitter (other than L-tryptophan),

15 C' is L-tryptophan, in the manufacture of a medicament for the treatment of at least one form of depression, particularly an endogenous depression.

- 20 2. Use according to claim 1, wherein the depression is chronic (cyclothymic) depression or acute (severe) nonpsychotic depression.
- 3. Use according to claim 1 or 2, wherein A is an antidepressant exhibiting SSRI or SNRI activity.
 - 4. Use according to claim 3, wherein A is lofepramine, fluoxetine, citalapram or paroxetine.
- 30 5. Use according to any one of claims 1 to 4, wherein B is in the form of cyanocobalamin or hydroxycobalamin.
 - 6. Use according to any one of claims 1 to 5, wherein C is L-phenylalanine, L-tyrosine, or tyramine.

WO 2004/110417

12

PCT/GB2004/002493

7. Use according to claim 1, wherein the combination of components is L-tryptophan and a SSRI.

8. Method of making a medicament for the treatment of a patient suffering from depression, particularly endogenous depression, comprising admixing any one of the following components or combinations of components:

C,

10 A and B,

A and C or C',

B and C or C',

A, B and C or C',

wherein

15 A is an antidepressant,

B is vitamin B_{12} , and

C is a precursor or inducer of a neurotransmitter (other than L-tryptophan),

C' is L-tryptophan,

with at least one pharmaceutically acceptable component or vehicle to prepare a medicament suitable for administration to a patient.

9. Method according to claim 8, wherein said
25 medicament contains one of the following combinations of components:

A, B and C or C',

A and B,

B and C or C',

A and C or C',

30

in a form or forms suitable for simultaneous or separate administration.

10. Method according to claim 8 or 9, wherein the

WO 2004/110417 PCT/GB2004/002493

depression is acute (severe) non-psychotic depression, or chronic depression.

- 11. Method according to any one of claims 8 to 10, wherein A is an antidepressant exhibiting SSRI or SNRI activity.
 - 12. Method according to claim 11, wherein A is lofepramine, fluoxetine, citalapram or paroxetine.
- 13. Method according to any one of claims 8 to 12, wherein B is in the form of cyanocobalamin or hydroxycobalamin.
- 15 14. Method according to any one of claims 8 to 14, wherein C is L-phenylalanine, L-tyrosine, or tyramine.
 - 15. Method according to any one of claims 8 to 11 wherein the combination of components is L-tryptophan and a SSRI.
 - 16. Method of treatment of a patient suffering from a form of depression, particularly endogenous depression, comprising administering to the patient any one of the following combinations of components:
 - I. A, B and C or C'
 - II. A and B
 - III. B and C or C'
 - IV. A and C or C'
- 30 wherein

20

25

- A is an antidepressant,
- B is vitamin B_{12} , and
- C is a precursor or inducer of a neurotransmitter (other than L-tryptophan),

WO 2004/110417 PCT/GB2004/002493

14

C' is L-tryptophan,

5

20

30

said components being administered simultaneously or separately, in amounts which in combination have the effect of ameliorating the depression.

17. Method according to claim 16 wherein the depression is chronic depression or acute (severe) non-psychotic depression.

- 18. Method according to any one of claims 18 to 20, wherein A is an antidepressant exhibiting SSRI or SNRI activity.
- 19. Method according to claim 18, wherein A is lofepramine, fluoxetine, citalapram or paroxetine.
 - 20. Method according to any one of claims 16 to 19, wherein B is in the form of cyanocobalamin or hydroxycobalamin.

21. Method according to any one of claims 16 to 20, wherein C is L-phenylalanine, L-tyrosine or tyramine.

- 22. Method according to claim 16, wherein the combination of components is L-tryptophan and a SSRI.
 - 23. A pharmaceutical composition for treatment of depression having a combination of pharmaceutically active components consisting only of or including any one of the combinations set out in claim 16.